On September 27, 2024, Alembic Pharmaceuticals announced that it had been given final approval from the US Food & Drug Administration (USFDA) for its Paliperidone Extended-Release Tablets in strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg. This approval is for a generic version of Invega Extended-Release Tablets developed by Janssen Pharmaceuticals. Paliperidone …